{"id":2709,"date":"2024-01-09T08:00:00","date_gmt":"2024-01-09T00:00:00","guid":{"rendered":"\/\/m.axcessimc.com\/?p=2709"},"modified":"2024-02-18T16:24:25","modified_gmt":"2024-02-18T08:24:25","slug":"%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%96%ae%e6%8a%97%e5%86%8d%e7%99%bb%e3%80%8a%e8%87%aa%e7%84%b6-%e9%86%ab%e5%ad%b8%e3%80%8b%ef%bc%8c%e5%8a%a9%e5%8a%9b%e4%b8%89%e9%99%b0%e6%80%a7%e4%b9%b3%e8%85%ba","status":"publish","type":"post","link":"\/\/m.axcessimc.com\/zh-hant\/%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%96%ae%e6%8a%97%e5%86%8d%e7%99%bb%e3%80%8a%e8%87%aa%e7%84%b6-%e9%86%ab%e5%ad%b8%e3%80%8b%ef%bc%8c%e5%8a%a9%e5%8a%9b%e4%b8%89%e9%99%b0%e6%80%a7%e4%b9%b3%e8%85%ba\/","title":{"rendered":"\u7279\u745e\u666e\u5229\u55ae\u6297\u518d\u767b\u300a\u81ea\u7136-\u91ab\u5b78\u300b\uff0c\u52a9\u529b\u4e09\u9670\u6027\u4e73\u817a\u764c\u60a3\u8005\u9577\u751f\u5b58"},"content":{"rendered":"\n
\u8fd1\u65e5\uff0c\u7531\u4e2d\u570b\u4eba\u6c11\u89e3\u653e\u8ecd\u7e3d\u91ab\u9662\u7b2c\u4e94\u91ab\u5b78\u4e2d\u5fc3\u6c5f\u6fa4\u98db\u6559\u6388\u727d\u982d\u958b\u5c55\u7684\u7279\u745e\u666e\u5229\u55ae\u6297\u806f\u5408\u767d\u86cb\u767d\u7d50\u5408\u578b\u7d2b\u6749\u9187(nab-P)\u6cbb\u7642\u9996\u8a3a\u2163\u671f\u6216\u5fa9\u767c\u8f49\u79fb\u6027\u4e09\u9670\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u7684\u2162\u671fTORCHLIGHT\u7814\u7a76\u6210\u679c\u7372\u570b\u969b\u9802\u5c16\u91ab\u5b78\u671f\u520a\u300a\u81ea\u7136-\u91ab\u5b78\u300b\uff08Nature Medicine<\/em>, IF=82.9\uff09\u767c\u8868\u3002\u9019\u662fTORCHLIGHT\u7814\u7a76\u69ae\u767b2023 ASCO\u5e74\u6703\u91cd\u78c5\u7814\u7a76\u6458\u8981\uff08LBA\uff09\u5feb\u901f\u6458\u8981\u5c08\u5834\u53e3\u982d\u5f59\u5831\u5f8c\uff0c\u518d\u6b21\u7372\u5f97\u570b\u969b\u5b78\u8853\u7684\u8a8d\u53ef\u3002<\/p>\n\n\n\n \u6c5f\u6fa4\u98db\u6559\u6388\u70ba\u672c\u6587\u7684\u901a\u8a0a\u4f5c\u8005\uff0c\u6e56\u5357\u7701\u816b\u7624\u91ab\u9662\u6b50\u967d\u53d6\u9577\u6559\u6388\u3001\u907c\u5be7\u7701\u816b\u7624\u91ab\u9662\u5b6b\u6fe4\u6559\u6388\u3001\u54c8\u723e\u6ff1\u91ab\u79d1\u5927\u5b78\u9644\u5c6c\u816b\u7624\u91ab\u9662\u5f35\u6e05\u5a9b\u6559\u6388\u70ba\u6587\u7ae0\u7684\u5171\u540c\u7b2c\u4e00\u4f5c\u8005\u3002<\/p>\n\n\n \u4e2d\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\u526f\u7406\u4e8b\u9577\u517c\u79d8\u66f8\u9577\u3001\u89e3\u653e\u8ecd\u7e3d\u91ab\u9662\u816b\u7624\u91ab\u5b78\u90e8\u526f\u4e3b\u4efb\u6c5f\u6fa4\u98db\u6559\u6388<\/strong>\u8868\u793a\uff1a\u201c\u7528\u4e2d\u570b\u7684\u7522\u54c1\u548c\u8a2d\u8a08\uff0c\u89e3\u6c7a\u570b\u4eba\u665a\u671f\u4e09\u9670\u4e73\u817a\u764c\u56f0\u5883\u7684\u514d\u75ab\u7642\u6cd5\uff0cTORCHLIGHT\u6536\u7a6b\u53ef\u559c\u7d50\u679c\uff0c\u8b93\u4e00\u90e8\u5206\u4e09\u9670\u4e73\u817a\u764c\u60a3\u8005\u6709\u6a5f\u6703\u5be6\u73fe\u9577\u751f\u5b58\u3002\u201d<\/p>\n\n\n\n \u541b\u5be6\u751f\u7269\u5168\u7403\u7814\u767c\u7e3d\u88c1\u9112\u5efa\u8ecd\u535a\u58eb<\/strong>\u8868\u793a\uff1a\u201c\u5f88\u9ad8\u8208\u770b\u5230TORCHLIGHT\u7814\u7a76\u518d\u767b\u65b0\u9ad8\uff0cTORCHLIGHT\u7814\u7a76\u7372\u5f97\u7684\u4e00\u7cfb\u5217\u6210\u529f\uff0c\u96e2\u4e0d\u958b\u60a3\u8005\u3001\u7814\u7a76\u8005\u8207\u7814\u767c\u5718\u968a\u7684\u5171\u540c\u52aa\u529b\u8207\u5949\u737b\uff0c\u8a72\u7814\u7a76\u7372\u5f97\u7684\u7a81\u7834\u6027\u6210\u679c\uff0c\u6709\u671b\u89e3\u6c7a\u81e8\u5e8a\u672a\u76e1\u4e4b\u9700\uff0c\u70ba\u4e2d\u570bTNBC\u60a3\u8005\u5e36\u4f86\u66f4\u512a\u7684\u6cbb\u7642\u9078\u64c7\u3002\u201d<\/p>\n\n\n\n TORCHLIGHT\u7814\u7a76\uff08NCT04085276\uff09\u662f\u570b\u5167\u9996\u500b\u5728\u665a\u671fTNBC\u514d\u75ab\u6cbb\u7642\u9818\u57df\u53d6\u5f97\u967d\u6027\u7d50\u679c\u7684\u2162\u671f\u8a3b\u518a\u7814\u7a76<\/strong>\uff0c\u572856\u5bb6\u4e2d\u5fc3\u958b\u5c55\uff0c\u81ea2018\u5e7412\u670825\u65e5\u81f32022\u5e7411\u670830\u65e5\uff0c\u5171\u5165\u7d44531\u4f8b\u9996\u8a3a\u2163\u671f\u6216\u5fa9\u767c\u8f49\u79fb\u6027TNBC\u60a3\u8005\uff0c\u4ee52:1\u7684\u6bd4\u4f8b\u96a8\u6a5f\u63a5\u53d7\u7279\u745e\u666e\u5229\u55ae\u6297\uff08240mg, Q3W\uff09\u6216\u5b89\u6170\u5291\u806f\u5408nab-P\uff08125mg\/m2, \u7b2c1\u5929\u548c\u7b2c8\u5929, Q3W\uff09\u6cbb\u7642\uff0c\u76f4\u5230\u75be\u75c5\u9032\u5c55\u6216\u8005\u51fa\u73fe\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u7b49\u60c5\u6cc1\u767c\u751f\u3002\u6309\u7167PD-L1\u8868\u9054\u60c5\u6cc1\uff08CPS\u22651 vs. CPS<1\uff09\u3001\u65e2\u5f80\u7d2b\u6749\u985e\u85e5\u7269\u6cbb\u7642\u53f2\uff08\u662f vs. \u5426\uff09\u3001\u76ee\u524d\u6cbb\u7642\u7dda\u6578\uff08\u4e00\u7dda vs. \u4e8c\u7dda\uff09\u9032\u884c\u5206\u5c64\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u76f2\u614b\u7368\u7acb\u4e2d\u5fc3\u8a55\u5be9\u59d4\u54e1\u6703\uff08BICR\uff09\u6839\u64daRECIST v1.1\u6a19\u6e96\u8a55\u4f30\u7684PD-L1\u967d\u6027\u4eba\u7fa4\u548c\u610f\u5411\u6027\u6cbb\u7642 (ITT) \u4eba\u7fa4\u7684\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u3002\u6b21\u8981\u7d42\u9ede\u5305\u62ec\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u30011\u5e74\u548c2\u5e74OS\u7387\u3001\u7814\u7a76\u8005\u8a55\u4f30\u7684PFS\u3001\u7814\u7a76\u8005\u548cBICR\u8a55\u4f30\u7684\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR)\u3001\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u3001\u7de9\u89e3\u6301\u7e8c\u6642\u9593\uff08DoR\uff09\u548c\u5b89\u5168\u6027\u3002<\/p>\n\n\n\n 353\u4f8b\u60a3\u8005\u96a8\u6a5f\u81f3\u7279\u745e\u666e\u5229\u55ae\u6297\u806f\u5408nab-P\u7d44\uff0c178\u4f8b\u60a3\u8005\u96a8\u6a5f\u81f3\u5b89\u6170\u5291\u806f\u5408nab-P\u7d44\uff0c\u5169\u7d44PD.1\u967d\u6027\u60a3\u8005\u5206\u5225\u6709200\u4f8b\u548c100\u4f8b\u3002\u7121\u8ad6ITT\u4eba\u7fa4\u548cPD-L1\u967d\u6027\u4e9e\u7d44\u4eba\u7fa4\uff0c\u5169\u7d44\u60a3\u8005\u7684\u57fa\u7dda\u4eba\u9580\u7d71\u8a08\u5b78\u548c\u75be\u75c5\u7279\u5fb5\u90fd\u5747\u8861\u3002<\/p>\n\n\n\n \u9810\u8a2d\u7684\u671f\u4e2d\u5206\u6790\u7d50\u679c\u986f\u793a\uff1a<\/p>\n\n\n\n \u57fa\u65bc\u8a72\u7814\u7a76\u7d50\u679c\uff0c\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u5df2\u65bc2023\u5e745\u6708\u6b63\u5f0f\u53d7\u7406\u7279\u745e\u666e\u5229\u55ae\u6297\u806f\u5408\u6ce8\u5c04\u7528\u7d2b\u6749\u9187\uff08\u767d\u86cb\u767d\u7d50\u5408\u578b\uff09\u7528\u65bcPD-L1\u967d\u6027\uff08CPS\u22651\uff09\u7684\u521d\u6cbb\u8f49\u79fb\u6216\u5fa9\u767c\u8f49\u79fb\u6027TNBC\u6cbb\u7642\u7684\u65b0\u9069\u61c9\u75c7\u4e0a\u5e02\u7533\u8acb\u3002<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n \u8fd1\u65e5\uff0c\u7531\u4e2d\u570b\u4eba\u6c11\u89e3\u653e\u8ecd\u7e3d\u91ab\u9662\u7b2c\u4e94\u91ab\u5b78\u4e2d\u5fc3\u6c5f\u6fa4\u98db\u6559\u6388\u727d\u982d\u958b\u5c55\u7684\u7279\u745e\u666e\u5229\u55ae\u6297\u806f\u5408\u767d\u86cb\u767d\u7d50\u5408\u578b\u7d2b\u6749\u9187(nab-P)\u6cbb […]<\/p>\n","protected":false},"author":3,"featured_media":2683,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[],"class_list":["post-2709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-21"],"yoast_head":"\n\n
\u3010\u53c3\u8003\u6587\u737b\u3011<\/h5>\n\n\n\n
1. Jiang, Z., Ouyang, Q., Sun, T. et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med (2024).<\/h5>\n\n\n\n
1. <\/em>\u672c\u6750\u6599\u65e8\u5728\u50b3\u905e\u524d\u6cbf\u8cc7\u8a0a\uff0c\u7121\u610f\u5411\u60a8\u505a\u4efb\u4f55\u7522\u54c1\u7684\u63a8\u5ee3\uff0c\u4e0d\u4f5c\u70ba\u81e8\u5e8a\u7528\u85e5\u6307\u5c0e\u3002<\/em><\/strong><\/h6>\n\n\n\n
2. \u82e5\u60a8\u60f3\u77ad\u89e3\u5177\u9ad4\u75be\u75c5\u8a3a\u7642\u8cc7\u8a0a\uff0c\u8acb\u9075\u5f9e\u91ab\u7642\u885b\u751f\u5c08\u696d\u4eba\u58eb\u7684\u610f\u898b\u8207\u6307\u5c0e\u3002<\/em><\/em><\/em><\/h6>\n","protected":false},"excerpt":{"rendered":"